Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 65,422
  • Shares Outstanding, K 54,518
  • Annual Sales, $ 103,780 K
  • Annual Income, $ 22,810 K
  • EBIT $ -1 M
  • EBITDA $ -1 M
  • 60-Month Beta 0.63
  • Price/Sales 0.61
  • Price/Cash Flow 2.25
  • Price/Book 0.96

Options Overview Details

View History
  • Implied Volatility 329.39% ( +4.81%)
  • Historical Volatility 49.40%
  • IV Percentile 87%
  • IV Rank 60.16%
  • IV High 536.50% on 06/03/24
  • IV Low 16.63% on 02/27/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 59
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,834
  • Open Int (30-Day) 1,428

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.24
  • Number of Estimates 2
  • High Estimate -0.21
  • Low Estimate -0.27
  • Prior Year 0.96
  • Growth Rate Est. (year over year) -125.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0100 +15.35%
on 10/30/24
1.3500 -13.70%
on 10/25/24
-0.1150 (-8.98%)
since 10/21/24
3-Month
1.0100 +15.35%
on 10/30/24
1.4500 -19.66%
on 08/26/24
-0.2000 (-14.65%)
since 08/21/24
52-Week
1.0100 +15.35%
on 10/30/24
1.8900 -38.36%
on 03/14/24
-0.0450 (-3.72%)
since 11/21/23

Most Recent Stories

More News
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Jazz Pharmaceuticals JAZZ announced that the FDA has granted accelerated approval to its intravenously administered drug zanidatamab for certain patients with biliary tract cancer (BTC). The drug will...

CTMX : 0.8683 (-0.21%)
JAZZ : 125.07 (+4.89%)
CSTL : 29.19 (+2.60%)
SPRO : 1.1600 (-3.33%)
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer

Puma Biotechnology, Inc. PBYI announced that it has initiated the phase II ALISCA-Breast1 study evaluating its pipeline candidate, alisertib, for the treatment of patients with metastatic breast cancer.The...

IMCR : 32.36 (-0.19%)
PBYI : 2.96 (+4.23%)
CSTL : 29.19 (+2.60%)
SPRO : 1.1600 (-3.33%)
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study

Sage Therapeutics’ SAGE phase II study evaluating its neuropsychiatric candidate, dalzanemdor (SAGE-718), for treating cognitive impairment (CI) associated with Huntington’s Disease (HD) failed to...

IMCR : 32.36 (-0.19%)
CSTL : 29.19 (+2.60%)
SAGE : 4.92 (+0.20%)
SPRO : 1.1600 (-3.33%)
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Shares of Grifols GRFS lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for €6.45 billion...

CTMX : 0.8683 (-0.21%)
CSTL : 29.19 (+2.60%)
GRFS : 8.45 (-1.74%)
SPRO : 1.1600 (-3.33%)
FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.Data showed...

IMCR : 32.36 (-0.19%)
CSTL : 29.19 (+2.60%)
FATE : 2.04 (-8.11%)
SPRO : 1.1600 (-3.33%)
Spero Therapeutics Advances Phase 3 Tebipenem HBr Trial, Reports Q3 Financial Results and Restructuring Efforts

Spero Therapeutics reports progress on tebipenem HBr trial; cash runway extended to mid-2026 amid restructuring.Quiver AI SummarySpero Therapeutics, Inc. announced its financial results for Q3 2024, reporting...

SPRO : 1.1600 (-3.33%)
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

SPRO : 1.1600 (-3.33%)
Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

SPRO : 1.1600 (-3.33%)
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update

SPRO : 1.1600 (-3.33%)
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

SPRO : 1.1600 (-3.33%)

Business Summary

Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 1.3267
2nd Resistance Point 1.2733
1st Resistance Point 1.2367
Last Price 1.1600
1st Support Level 1.1467
2nd Support Level 1.0933
3rd Support Level 1.0567

See More

52-Week High 1.8900
Fibonacci 61.8% 1.5538
Fibonacci 50% 1.4500
Fibonacci 38.2% 1.3462
Last Price 1.1600
52-Week Low 1.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar